Viatris
Viatris is a global healthcare company formed through the combination of Mylan and Pfizer's Upjohn business, specializing in a diverse portfolio of medicines including iconic brands, generics, and complex products. The company leverages a massive global supply chain and R&D infrastructure to provide high-quality treatments to approximately one billion patients annually across more than 165 countries. Its core value proposition centers on 'access at scale,' bridging the gap between traditional generic manufacturing and innovative branded pharmaceuticals.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Brands
primaryThis category includes patent-protected innovative medicines and iconic legacy brands that are highly sensitive to promotion and marketing. It also encompasses branded generics, which are off-patent products sold under proprietary names, primarily in emerging markets.
Lipitor, Lyrica, Celebrex, Viagra, Norvasc, EpiPen Auto-Injector, Effexor, Creon, Influvac
Physicians, Hospitals, Retail Pharmacies, Governments
Generics
majorA high-volume business focused on therapeutically equivalent versions of brand-name drugs sold under International Nonproprietary Names (INNs). This segment provides essential cost savings to healthcare systems and patients through lower-margin, high-scale distribution.
Wixela Inhub, Glatiramer Acetate Injection, Iron Sucrose Injection, Pomalidomide, Dapagliflozin
Wholesalers, Distributors, Retail Pharmacies, Institutional Pharmacies
Complex Products
moderateFocuses on medicines with complex active ingredients, formulations, or delivery systems, such as injectables and inhalers. These products typically face limited competition due to the technical difficulty of development and manufacturing.
Breyna, Wixela Inhub, Restasis (generic), Venofer (generic)
Specialty Pharmacies, Hospitals, Payers
Segment Financials
Brands — Net Sales
View metricLipitor — Net Sales
View metricViagra ® — Net Sales
View metricGenerics — Net Sales
View metricYupelri ® — Net Sales
View metricDeveloped Markets Segment — Cost of Sales
View metricEpiPen® Auto-Injectors — Net Sales
View metricBusiness Overview
Competitive Position
A leading global provider of medicines with a unique hybrid model that combines a massive generic portfolio with iconic established brands and a growing innovative pipeline.
Geographies
North America, Europe, China, Japan, Australia, India
Customer Segments
Wholesalers, Retailers, Governments, Healthcare Providers
Upstream Dependencies
Active Pharmaceutical Ingredient (API) suppliers, Contract Manufacturing Organizations (CMOs), Raw material providers, Clinical trial partners
Downstream Customers
Pharmaceutical wholesalers, Retail pharmacy chains, Hospitals and health systems, Government health agencies, Insurance companies
Competitors & Partners
Competitors
Similar Companies
Roivant Sciences
ROIV
West Pharmaceutical Services
WST
Biogen
BIIB
Bristol-Myers Squibb
BMY
AbbVie
ABBV
Merck & Co.
MRK
Royalty Pharma
RPRX
Johnson & Johnson
JNJ
Alnylam Pharmaceuticals
ALNY
United Therapeutics
UTHR
Abbott
ABT
Cardinal Health
CAH
Gilead Sciences
GILD
Kenvue
KVUE
Becton, Dickinson and Company
BDX
Vertex Pharmaceuticals
VRTX
Partners
Biocon Biologics
Strategic partner following the contribution of Viatris' biosimilars portfolio for an equity stake
Insud Pharma, S.L.
Acquirer of Viatris' women's healthcare business
Cooper Consumer Health
Acquirer of Viatris' Over-the-Counter (OTC) business
Theramex HQ UK Limited
Acquirer of rights to specific women's healthcare products
Matrix Pharma Private Limited
Acquirer of Viatris' API business in India
Subsidiaries
Aculys Pharma
Clinical stage biopharmaceutical company acquired in 2025 focused on neurological conditions in Japan
Mylan
Predecessor entity and core component of the Viatris combination
Viatris FAQ
Common questions about Viatris
Viatris is a global healthcare company formed through the combination of Mylan and Pfizer's Upjohn business, specializing in a diverse portfolio of medicines including iconic brands, generics, and complex products. The company leverages a massive global supply chain and R&D infrastructure to provide high-quality treatments to approximately one billion patients annually across more than 165 countries. Its core value proposition centers on 'access at scale,' bridging the gap between traditional generic manufacturing and innovative branded pharmaceuticals.
Viatris (VTRS) has a market capitalization of $19.2B and trades on NASDAQ.
Viatris generated $14.6B in trailing twelve-month revenue with a net loss of $296.5M, representing a net margin of -2.0%. Gross margin stands at 34.4%, with free cash flow of $1.8B. These figures are based on the Q1 2026 filing.
Viatris's key competitors include Pfizer Inc., Cencora, Inc., McKesson Corporation, and others. These companies compete in similar markets and product categories.
Viatris has approximately 38,000 employees.